Johnson & Johnson earns CE Mark for new surgical stapler aimed at reducing complications

Johnson & Johnson has received European CE Mark approval for its ETHICON 4000 Stapler, a new surgical stapling device designed to improve staple line integrity across a range of tissue thicknesses in open and laparoscopic procedures, the company announced.

The ETHICON 4000 Stapler, paired with ETHICON 3D Reloads, incorporates proprietary 3D stapling technology, a redesigned end-effector and simplified reload options. The device is now certified for use across the European Union and is expected to be integrated in the future with the company’s OTTAVA robotic surgical system, which remains under development.

“Surgical complications, including leaks and bleeding events, can impact surgical outcomes, causing distress to both patients and surgeons, and are associated with significant cost implications,” François Gaudemet, president of surgery for Europe, the Middle East and Africa at Johnson & Johnson MedTech, said in a statement. “We are building on a long legacy of supporting surgeons and driving innovation for consistent and reliable experiences across open, minimally invasive and robotic surgery.”

The company said the device is intended to address longstanding challenges surgeons face when stapling thick, fragile or inconsistent tissue, factors that can compromise staple line integrity and increase the risk of leaks or bleeding.

One study cited in the release found that bariatric surgeons reinforced the staple line through oversewing, buttressing or both in 77% of laparoscopic sleeve gastrectomy cases, underscoring the need for improved staple reliability.

The economic burden of surgical complications also remains significant. According to data referenced by Johnson & Johnson, prolonged air leaks occurred in 27% of thoracic surgery patients in the United Kingdom, adding an average of €5,200 in postoperative costs per patient over 90 days. A separate Swiss study found that bleeding events occurred in 8% of thoracic procedures, adding more than €26,000 per case.

Johnson & Johnson said real-world evidence since 2017 has shown its surgical stapling devices are associated with improved clinical and economic outcomes in bariatric, thoracic and colorectal surgeries across multiple countries and patient populations.

The company noted that its OTTAVA robotic platform is still under development and is not yet authorized for sale in any market.

Advanced stapling technologies continue to reshape surgical workflows

Advances in surgical stapling technology are becoming increasingly important as hospitals seek to reduce postoperative complications, improve efficiency and support the shift toward minimally invasive and robotic procedures.

Modern stapling systems are being engineered with greater adaptability to varying tissue thickness, a longstanding challenge in surgery that can lead to leaks, bleeding and tissue trauma when staples are improperly formed. Innovations such as enhanced articulation, real-time feedback mechanisms and improved staple formation designs are helping surgeons achieve more consistent outcomes across a broader range of procedures.

The trend is particularly important in minimally invasive surgery, where limited access and visibility can make precision more difficult. Newer stapling devices are designed to offer better maneuverability in confined anatomical spaces while maintaining secure closure of vessels and tissue. This can be especially valuable in thoracic, colorectal and bariatric surgeries, where staple line integrity is critical to patient recovery.

Robotic surgery is also driving development in the sector. Stapling systems compatible with robotic platforms are being designed to give surgeons greater control, allowing for precise placement and activation from the console. This integration aligns with broader industry efforts to create connected operating room ecosystems in which surgical devices share data and help guide intraoperative decisions.

At the same time, health care providers are increasingly focused on the economic impact of surgical complications. Stapling innovations that reduce leaks, bleeding events and operative time may help lower readmissions and postoperative costs while improving patient outcomes. As hospitals continue to evaluate value-based technologies, advanced stapling platforms are emerging as an important area of investment within surgical care.